| Objective:It is to explore the human umbilical cord blood mesenchymal stem cells (UC-MSCs) transplantation by hepatic artery in treatment of decompensated liver cirrhosis and clinical efficacy. And then through the human umbilical cord blood mesenchymal stem cells for treatment of clinical efficacy in patients with liver failure, further evaluation of change detection index for application of umbilical cord blood mesenchymal stem cells and its significance in treatment of patients with liver failure.Methods:2009April to2011April implementation choice of umbilical cord blood mesenchymal stem cell transplantation in treatment of liver cirrhosis compensatory stage in the first hospital of Zibo city (1, have history lead to cirrhosis of the liver.2, there is clinical manifestations of liver dysfunction and/or portal hypertension.3, liver function, albumin decreased suggesting elevated bilirubin or prolonged prothrombin time tips hepatic decompensation.4, ultrasound or CT liver cirrhosis or endoscopy showed esophageal varices performance) in44patients. Preoperative routine Liver-protective therapy, technology application (bone marrow cells from umbilical cord blood Wilson application of stem cell treatment kit SCR-200Ⅰ or Ⅱ SCR-200), from cord blood (as far as possible to choose for the term, the baby’s umbilical cord blood80-100ml) extracted from mesenchymal stem cells (by blood cell counter and manual counting method count0.8x107-5.4x109), method of transcatheter hepatic arterial injection of hepatic artery. Stem cell transplantation after first,4,10and16weeks of observation of serum transaminase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB) and fibrinogen (FIB) level, and observe the clinical symptoms and signs (especially ascites volume change) improvement and adverse reaction. After transplantation to observe clinical indicators include3parts: one is the symptoms and signs of the patients; two is the review of serum transaminase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB) and fibrinogen (FIB) level and other laboratory indexes; three is the relevant examination review images. Tenth,16weeks on abdominal CT imaging evaluation of liver volume (in portal vein branch plane area indicates liver volume and liver) about changes of leaf maximum diameter change, portal vein width indicator. Statistical analysis was carried out, using SPSS10software, count data expressed as a ratio, chi-square test, P <0.05had significant difference.Results:Umbilical cord blood mesenchymal stem cell transplantation after2weeks, liver function index and the before treatment showed no significant difference; after4weeks of treatment, serum albumin was increased, compared with before treatment, P<0.05, alanine aminotransferase and aspartate aminotransferase were also improved (P<0.05), no significant improve the remaining indicators;10weeks after treatment follow-up liver function indexes (including serum albumin, alanine aminotransferase, aspartate transaminase and esterase) were significantly improved (P <0.05). And the prothrombin time in stem cell therapy after4weeks, significantly shorter than before treatment (normal prothrombin time value is12-14seconds, treatment of prothrombin time above10-20%normal value), P<0.05,10weeks after treatment compared with before treatment, P<0.01; prothrombin activity after treatment in4weeks respectively, compared with the treatment of L6increased significantly, P<0.01. After treatment, the clinical symptoms and signs of4weeks in most patients improved significantly, ascites (through the method of measurement of body weight and daily measured abdominal circumference) and lower extremity pitting edema was relieved in33cases (75%), fatigue (through improved patient complained of)35cases (80%), appetite improved in29cases (65%), jaundice in35cases (80%); sixteenth weeks after operation on abdominal CT showed liver volume and liver left lobe of the maximal diameters were increased (for treatment before liver volume reduced)(P<0.05). L2weeks after the overall patient survival rate was97.7%,1patients in the umbilical cord blood mesenchymal stem cells in4weeks after transplantation for hepatic coma and death (considered as non transplant related). Mesenchymal stem cell transplantation in patients with no adverse reactions related to the. Visible, the characteristics of umbilical cord blood mesenchymal stem safety and efficacy have higher cell loss compensatory stage of cirrhosis of the liver in the treatment of the disease.Conclusion:1umbilical cord blood mesenchymal stem cells via hepatic artery transplantation is the treatment of decompensated cirrhosis of the liver is a safe and effective method, umbilical cord blood stem cell transplantation therapy can effectively repair liver cell damage, improve liver function and quality of life in patients, especially worthy of recognition in the improvement of decompensated liver cirrhosis patients with clinical symptoms and signs.2by postoperative follow-up patient liver function (serum albumin, alanine aminotransferase, aspartate aminotransferase and cholinesterase), found that PT, PTA, FIB and other indicators, these indicators are indicators of umbilical cord blood mesenchymal stem cells in the treatment of decompensated cirrhosis is very important in blood. Regular monitoring of patients after operation on abdominal CT through the liver volume, liver or determination of leaf maximum cross section diameter is observed monitoring index of good image, these indexes to evaluate the therapy efficiency. |
PDF Full Text Request